Similarly, ADAM17 activates the EGFR-PI3K-AKT pathway in glioma, resulting in enhanced proliferation, invasion, and angiogenesis, and inhibition of ADAM17, which significantly reduce tumour growth in mice [108]. This evidence concerns the gene ADAM17 and central nervous system cancer.